{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "POSTPOST", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 3.01, "exchange": "CXE", "longName": "Biofrontera AG", "exchangeTimezoneName": "Europe/London", "market": "gb_market", "regularMarketTime": 1683183816, "regularMarketPreviousClose": 3.01, "fullExchangeName": "Cboe UK", "financialCurrency": "EUR", "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.22333503, "fiftyTwoWeekLowChangePercent": 0.0801442, "fiftyTwoWeekRange": "2.786665 - 3.01", "fiftyTwoWeekHighChange": 0.0, "fiftyTwoWeekHighChangePercent": 0.0, "fiftyTwoWeekLow": 2.786665, "fiftyTwoWeekHigh": 3.01, "earningsTimestamp": 1682593140, "earningsTimestampStart": 1682593140, "earningsTimestampEnd": 1682593140, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.34, "bookValue": 0.319, "fiftyDayAverage": 2.78667, "fiftyDayAverageChange": 0.22333002, "fiftyDayAverageChangePercent": 0.08014226, "twoHundredDayAverage": 2.8514357, "twoHundredDayAverageChange": 0.15856433, "twoHundredDayAverageChangePercent": 0.055608593, "priceToBook": 9.435737, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1422518400000, "priceHint": 4, "regularMarketChange": 0.0, "symbol": "B8FD.XC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Hemmelrather Weg 201", "city": "Leverkusen", "zip": "51377", "country": "Germany", "website": "https://www.biofrontera.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; and Belixos, a medical skin care series for irritated and sensitive skin. It has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.", "fullTimeEmployees": 110, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ludwig M. Lutter", "age": 55, "title": "Member of the Exec. Board", "yearBorn": 1967, "fiscalYear": 2021, "totalPay": {"raw": 288200, "fmt": "288.2k", "longFmt": "288,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Pilar  de la Huerta", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alexander  Richardson", "title": "Head of UK Sales Team", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Matthias  Naumann", "title": "Head of Sales & Marketing - Europe", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Montserrat  Foguet Ph.D.", "title": "Managing Director of Biofrontera UK Ltd.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}